Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 15;59 Suppl 7(Suppl 7):S437-44.
doi: 10.1093/cid/ciu709.

Designing drug trials: considerations for pregnant women

Jeanne S Sheffield  1 , David Siegel  2 , Mark Mirochnick  3 , R Phillips Heine  4 , Christine Nguyen  5 , Kimberly L Bergman  6 , Rada M Savic  7 , Jill Long  8 , Kelly E Dooley  9 , Mirjana Nesin  8
Affiliations

Designing drug trials: considerations for pregnant women

Jeanne S Sheffield et al. Clin Infect Dis. .

Abstract

Clinical pharmacology studies that describe the pharmacokinetics and pharmacodynamics of drugs in pregnant women are critical for informing on the safe and effective use of drugs during pregnancy. That being said, multiple factors have hindered the ability to study drugs in pregnant patients. These include concerns for maternal and fetal safety, ethical considerations, the difficulty in designing appropriate trials to assess the study objectives, and funding limitations. This document summarizes the recommendations of a panel of experts convened by the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. These experts were charged with reviewing the issues related to the development of preclinical and clinical drug studies in pregnant women and to develop strategies for addressing these issues. These findings may also be utilized in the development of future drug studies involving pregnant women and their fetus/neonate.

Keywords: drug trials; pharmacokinetics; pregnancy.

PubMed Disclaimer

References

    1. Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205:51. e1–8. - PMC - PubMed
    1. Gee RE, Wood SF, Schubert KG. Women's health, pregnancy, and the U.S. Food and Drug Administration. Obstet Gynecol. 2014;123:161–5. - PubMed
    1. Broussard CS, Frey MT, Hernandez-Diaz S, et al. Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention–convened meeting. Am J Obstet Gynecol. 2014;211:208–14. - PMC - PubMed
    1. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191:398–407. - PubMed
    1. Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal ham among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15:546–54. - PubMed

Publication types